ICON Public Limited (NASDAQ:ICLR) Position Increased by Park Place Capital Corp

Park Place Capital Corp lifted its position in shares of ICON Public Limited (NASDAQ:ICLR) by 281.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 225 shares of the medical research company’s stock after acquiring an additional 166 shares during the period. Park Place Capital Corp’s holdings in ICON Public were worth $47,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC boosted its position in ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after acquiring an additional 169 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of ICON Public by 39.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock worth $129,000 after acquiring an additional 111 shares in the last quarter. Whittier Trust Co. of Nevada Inc. boosted its position in shares of ICON Public by 23.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock valued at $147,000 after purchasing an additional 96 shares during the period. First Horizon Advisors Inc. increased its position in shares of ICON Public by 33.9% in the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after acquiring an additional 151 shares in the last quarter. Finally, Steph & Co. grew its position in ICON Public by 3.7% during the 4th quarter. Steph & Co. now owns 1,560 shares of the medical research company’s stock worth $327,000 after purchasing an additional 55 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. lowered their target price on ICON Public from $375.00 to $280.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. TD Cowen decreased their price objective on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating for the company in a report on Friday, October 25th. Citigroup lowered their price target on ICON Public from $300.00 to $290.00 and set a “buy” rating on the stock in a report on Monday, January 6th. The Goldman Sachs Group lowered their price target on ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $255.00 target price (down previously from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $287.00.

ICON Public Stock Performance

Shares of NASDAQ:ICLR opened at $202.68 on Friday. The stock has a market capitalization of $16.72 billion, a price-to-earnings ratio of 22.60, a price-to-earnings-growth ratio of 1.54 and a beta of 1.20. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. The business’s fifty day moving average price is $209.32 and its two-hundred day moving average price is $264.99. ICON Public Limited has a fifty-two week low of $183.38 and a fifty-two week high of $347.72.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The business had revenue of $2.03 billion for the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the prior year, the business earned $3.10 earnings per share. As a group, analysts predict that ICON Public Limited will post 13.44 EPS for the current fiscal year.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.